ArticleOncotarget2017
The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 77 citations in OpenAlex.
- GCN2 in Cancer: Molecular Mechanisms to Therapeutic Potential.Current cancer drug targets · 2026Review
- Global research landscape and hotspots for ferroptosis in glioma: A comprehensive bibliometric and visual analysis.Heliyon · 2025Review
- The amino acid transporter SLC7A11 expression in breast cancer.Cancer biology & therapy · 2024Article
- Ferroptosis in glioma therapy: advancements in sensitizing strategies and the complex tumor-promoting roles.Brain research · 2024Review
- Dihydroartemisinin induces ferroptosis in T cell acute lymphoblastic leukemia cells by downregulating SLC7A11 and activating the ATF4‑CHOP signaling pathway.Oncology letters · 2024Article
- Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells.Science advances · 2024Article
- The Regulation of Ferroptosis by Noncoding RNAs.International journal of molecular sciences · 2023Review
- Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil.Biomedicines · 2023Review
- The crosslinks between ferroptosis and autophagy in asthma.Frontiers in immunology · 2023Review
- Ferroptosis and PPAR-gamma in the limelight of brain tumors and edema.Frontiers in oncology · 2023Review
- Adaptive Changes Allow Targeting of Ferroptosis for Glioma Treatment.Cellular and molecular neurobiology · 2022Review
- Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer.Cell death & disease · 2022Article
- Potential to Eradicate Cancer Stemness by Targeting Cell Surface GRP78.Biomolecules · 2022Review
- Ferroptosis Modulation: Potential Therapeutic Target for Glioblastoma Treatment.International journal of molecular sciences · 2022Review
- Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.BMC neurology · 2022Article
- Transcription Factors with Targeting Potential in Gliomas.International journal of molecular sciences · 2022Review
- Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.BMC cancer · 2022Article
- The Mechanisms of Ferroptosis and the Applications in Tumor Treatment: Enemies or Friends?Frontiers in molecular biosciences · 2022Review
- Emerging role of ferroptosis in glioblastoma: Therapeutic opportunities and challenges.Frontiers in molecular biosciences · 2022Review
- Emerging roles of ferroptosis in glioma.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant gliomas are devastating neoplasia with limited curative treatment options. Temozolomide (TMZ, Temcat
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.